At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
Belumosudil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy, Tolerability, and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
In Brief
A Phase 2 clinical trial evaluating Belumosudil and Placebo for Chronic Plaque Psoriasis. Completed, enrolled 110 participants across 14 sites.
Detailed Summary
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionFeb 2019
TodayJul 2026
First PostedAug 2, 2016
Enrollment StartSep 14, 2016
Primary CompletionFeb 13, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.9 years ago
Interventions
Belumosudildrug
Placebodrug
Placebo tablets matching belumosudil